Intrinsiqq
Immuneering Corporation logo

Immuneering Corporation Insider Trading

IMRX

Compare
Last 12 months

Insiders bought 360K on the open market and sold nothing.

Net open-market
+360K
8 buys · 0 sales
Under a 10b5-1 plan
—
no sales
Insiders who bought / sold
7 / 0
executives and directors
Last open-market buy
Nov 2026
Nov 13, 2026

Get an email when IMRX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Nov 13
    Andrew Gengos
    Chief Financial Officer · bought 25,000 at $3.58
    90K
    11% of stake
  • Jun 23
    Benjamin J. Zeskind
    President and CEO · bought 2,400 at $4.56
    11K
    <0.1% of stake
  • Jun 15
    Brett Matthew Hall
    Chief Scientific Officer · bought 6,035 at $4.15
    25K
    1.6% of stake
  • Jan 16
    Harold Eugene Brakewood
    Chief Business Officer · bought 5,250 at $4.76
    25K
    91% of stake
  • Jan 15
    Thomas J. Schall
    Director · bought 21,645 at $4.67
    101K
    41% of stake
  • Jan 15
    Brett Matthew Hall
    Chief Scientific Officer · bought 2,298 at $4.57
    11K
    0.6% of stake
  • Jan 13
    Leah R Neufeld
    Chief People Officer · bought 2,626 at $4.15
    11K
    11% of stake
  • Jan 12
    Peter Feinberg
    Director · bought 20,000 at $4.35
    87K
    1.8% of stake
  • Oct 3, 2025
    Peter Feinberg
    Director · bought 7,500 at $6.67
    50K
    0.7% of stake
  • Oct 1, 2025
    Mallory Morales
    Chief Accounting Officer · bought 300 at $6.39
    2K
    1.1% of stake
  • Oct 1, 2025
    Leah R Neufeld
    Chief People Officer · bought 800 at $6.38
    5K
    3.5% of stake
  • Oct 1, 2025
    Michael Bookman
    Chief Legal Officer, Secretary · bought 1,020 at $6.83
    7K
    26% of stake
  • Sep 30, 2025
    Peter Feinberg
    Director · bought 7,500 at $7.03
    53K
    0.7% of stake
  • Sep 29, 2025
    Peter Feinberg
    Director · bought 5,000 at $7.18
    36K
    0.4% of stake
  • Jul 2, 2025
    Diana Hausman
    Director · bought 5,500 at avg $3.61
    20K
    New position
  • Jul 2, 2025
    Leah R Neufeld
    Chief People Officer · bought 700 at $3.57
    2K
    7.0% of stake
  • Jul 1, 2025 – Jul 2, 2025
    Benjamin J. Zeskind
    President and CEO · bought 10,000 at avg $3.49
    35K
    0.3% of stake
  • Jun 27, 2025
    Thomas J. Schall
    Director · bought 9,500 at $3.66
    35K
    22% of stake
  • Jun 20, 2025 – Jun 23, 2025
    Brett Matthew Hall
    Chief Scientific Officer · bought 13,422 at avg $2.58
    35K
    3.9% of stake
  • Jun 20, 2025
    Harold Eugene Brakewood
    Chief Business Officer · bought 1,900 at $2.53
    5K
    49% of stake
  • Jun 18, 2025
    Peter Feinberg
    Director · bought 25,000 at $2.53
    63K
    2.3% of stake
  • Jun 18, 2025
    Benjamin J. Zeskind
    President and CEO · bought 21,000 at $2.39
    50K
    0.7% of stake
  • Jun 17, 2025
    Thomas J. Schall
    Director · bought 40,485 at $2.21
    89K
    1396% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch IMRX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with IMRX

CompareIntrinsic value
ALLRAllarity Therapeutics Inc.
$0.79-8.82%0
CRVOCervoMed Inc.
$1.45+8.65%10
PVCTProvectus Biopharmaceuticals, Inc.
$0.05+1.11%6
ABVCABVC BioPharma Inc.
$0.87-1.56%0
CYDYCytoDyn Inc.
$0.22-3.43%0
LIPOLipella Pharmaceuticals Inc.
$0.00+0.00%25
RGBPRegen Biopharma Inc.
$0.00-50.00%25
CANFCan-Fite BioPharma Ltd.
$1.44-2.04%20

Held by ETFs

IMRX is in 6 US ETFs. The largest of them, with IMRX's weight in each:

Spot a number that looks wrong? Check it in IMRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing IMRX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.